Abemaciclib (LY2835219) is an orally bioavailable, selective CDK4/6 inhibitor (IC50: 2 nM, 10 nM). It blocks retinoblastoma protein phosphorylation, inducing G1 phase arrest. Abemaciclib exhibits antitumor activity alone or in combination with other therapies in xenograft models. Reagent grade, for research purpose.
Usually ships within 24 hours.